Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...

For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several ...

Blood centres cannot make cell therapies more accessible on their own. For decades they have partnered with hospitals to ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

Now, in 2025, we expect the life sciences industry will scale its use of GenAI with greater purpose. As these applications ...

Where early enthusiasm around IDMP programmes had waned in response to slow progress from EMA in Europe towards clarifying ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...